Search

Your search keyword '"Caracciolo, D"' showing total 411 results
Start Over Author "Caracciolo, D"
411 results on '"Caracciolo, D"'

52. MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells

Author

Botta, C, primary, Cucè, M, additional, Pitari, M R, additional, Caracciolo, D, additional, Gullà, A, additional, Morelli, E, additional, Riillo, C, additional, Biamonte, L, additional, Gallo Cantafio, M E, additional, Prabhala, R, additional, Mignogna, C, additional, Di Vito, A, additional, Altomare, E, additional, Amodio, N, additional, Di Martino, M T, additional, Correale, P, additional, Rossi, M, additional, Giordano, A, additional, Munshi, N C, additional, Tagliaferri, P, additional, and Tassone, P, additional

Published
2017
Full Text
View/download PDF

54. Factors influencing the occurrence of secondary malignancies in high-risk lymphoma patients following high-dose therapy and autograft

Author

Tarella C, Passera R, Magni M, Rossi A, Benedetti F, Gueli A, Ruella M, Patti C, Parvis G, Gallamini A, Cortelazzo S, Corradini P, Zoli V, Mule A, Crocchiolo R, Bosa M, Barbui A, Di Nicola M, Caracciolo D, Sorio M, Gianni AM, Rambaldi A., CICERI , FABIO, Tarella, C, Passera, R, Magni, M, Rossi, A, Benedetti, F, Gueli, A, Ruella, M, Patti, C, Parvis, G, Ciceri, Fabio, Gallamini, A, Cortelazzo, S, Corradini, P, Zoli, V, Mule, A, Crocchiolo, R, Bosa, M, Barbui, A, Di Nicola, M, Caracciolo, D, Sorio, M, Gianni, Am, and Rambaldi, A.

Published
2010

55. Patients with aaIPI 2-3 diffuse large B-cell lymphoma achieve 75% long-term survival following first-line rituximab-supplemented high-dose sequential chemotherapy and autograft: Final results of the prospective phase II GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) trial

Author

Tarella C, Zanni M, Di Nicola M, Patti C, Castellino C, Crocchiolo R, Zoli V, Caracciolo D, Magni M, Boccadoro M, Corradini P, Gallamini A, Majolino I, Mirto S, Gianni AM, CICERI , FABIO, Tarella, C, Zanni, M, Di Nicola, M, Patti, C, Castellino, C, Crocchiolo, R, Zoli, V, Caracciolo, D, Magni, M, Boccadoro, M, Ciceri, Fabio, Corradini, P, Gallamini, A, Majolino, I, Mirto, S, and Gianni, Am

Published
2007

59. Graft-versus-lymphoma effect in peripheral T-cell lymphomas (PTCL): Reduced-intensity conditioning followed by allogeneic transplantation gives a better outcome than high-dose chemotherapy followed by autografting

Author

Corradini P, Dodero A, Zallio F, Cuttica A, Caracciolo D, Di Nicola M, Casini M, Narni F, Patriarca F, Boccadoro M, Gianni AM, Tarella C., CICERI , FABIO, Corradini, P, Dodero, A, Zallio, F, Cuttica, A, Caracciolo, D, Di Nicola, M, Casini, M, Ciceri, Fabio, Narni, F, Patriarca, F, Boccadoro, M, Gianni, Am, and Tarella, C.

Published
2003

64. A thermogravimetric study on tannery sewage sludges

Author

Ciambelli, P., Sannino, D., Vaiano, V., Caracciolo, D., Naviglio, B., and Gianluigi Calvanese

Subjects
ICP-AES, Tannery sewage sludges, Thermal behavior, GC-MS, Purge and trap GC-MS, TG-DSC-MS, Industrial and Manufacturing Engineering
Published
2013

65. Mathematical modelling of a vegetable tanning process

Author

Sannino, D., Vincenzo Vaiano, Ciambelli, P., Manna, A. M., Caracciolo, D., Naviglio, B., and Calvanese, G.

Subjects
Materials Science (all), Chemical Engineering (all), Chemistry (all)
Published
2013

75. MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells

Author

Botta, C, Cucè, M, Pitari, M R, Caracciolo, D, Gullà, A, Morelli, E, Riillo, C, Biamonte, L, Gallo Cantafio, M E, Prabhala, R, Mignogna, C, Di Vito, A, Altomare, E, Amodio, N, Di Martino, M T, Correale, P, Rossi, M, Giordano, A, Munshi, N C, Tagliaferri, P, and Tassone, P

Abstract

Dendritic cells (DCs) have a key role in regulating tumor immunity, tumor cell growth and drug resistance. We hypothesized that multiple myeloma (MM) cells might recruit and reprogram DCs to a tumor-permissive phenotype by changes within their microRNA (miRNA) network. By analyzing six different miRNA-profiling data sets, miR-29b was identified as the only miRNA upregulated in normal mature DCs and significantly downregulated in tumor-associated DCs. This finding was validated in primary DCs co-cultured in vitro with MM cell lines and in primary bone marrow DCs from MM patients. In DCs co-cultured with MM cells, enforced expression of miR-29b counteracted pro-inflammatory pathways, including signal transducer and activator of transcription 3 and nuclear factor-κB, and cytokine/chemokine signaling networks, which correlated with patients’ adverse prognosis and development of bone disease. Moreover, miR-29b downregulated interleukin-23 in vitro and in the SCID-synth-hu in vivo model, and antagonized a Th17 inflammatory response. All together, these effects translated into strong anti-proliferative activity and reduction of genomic instability of MM cells. Our study demonstrates that MM reprograms the DCs functional phenotype by downregulating miR-29b whose reconstitution impairs DCs ability to sustain MM cell growth and survival. These results underscore miR-29b as an innovative and attractive candidate for miRNA-based immune therapy of MM.

Published
2018
Full Text
View/download PDF

80. High-dose sequential (HDS) chemotherapy with blood and marrow cell autograft as salvage treatment in very poor prognosis, relapsed non-Hodgkin's lymphoma

Author

Caracciolo, D., Gavarotti, P., Aglietta, M., Bondesan, P., Falda, M., Gallo, E., Locatelli, F., Novarino, A., Paolino, F., Sanavio, F., Urgesi, A., umberto vitolo, and Tarella, C.

Subjects
Adult, Male, Lymphoma, Non-Hodgkin, Hematopoietic Stem Cell Transplantation, Middle Aged, Hematopoietic Stem Cells, Prognosis, Transplantation, Autologous, Methotrexate, Recurrence, Antineoplastic Combined Chemotherapy Protocols, Humans, Blood Transfusion, Female, Cyclophosphamide, Melphalan, Bone Marrow Transplantation, Etoposide
Abstract

We tested the feasibility and efficacy of a novel high-dose sequential chemoradiotherapy programme (HDS) in 14 relapsed or refractory non-Hodgkin's lymphoma patients with very poor prognostic features, i.e. transformed histology, marrow invasion, low performance status. This regimen included the sequential administration of high-dose cyclophosphamide (CY) 7 g/m2 followed by high-dose methotrexate (MTX) 8 g/m2 and high-dose VP16 2 g/m2 and finally by total body irradiation (TBI)-melphalan and autograft of bone marrow and peripheral blood progenitor cells. No hemopoietic growth factor support was employed in any phase. There was one treatment-related death during the high-dose phase; three other patients did not complete the programme. All 10 patients concluding the programme achieved complete remission, with four patients in complete clinical remission at a median follow up of 34 months. Median overall survival was 27 months and median failure-free survival (FFS) was 12 months. Twenty-six well comparable patients received conventional salvage therapy during the same period. Their projected median overall survival (8 months) and median FFS (4 months) were shorter than in the HDS group (p = 0.06 for overall survival and p = 0.03 for FFS). Thus, HDS is a feasible programme and may offer superior results than conventional therapy in poor-prognosis NHL patients.

Published
1993

91. Use of peripheral blood stem cells to accelerate hemopoietic recovery following autologous bone marrow transplantation

Author

Tarella, C, Gavarotti, P, Caracciolo, D, Locatelli, Franco, Falda, M, Paolino, F, Lovisone, E, Sormano, E, Tassi, V, Urgesi, A, Locatelli, F (ORCID:0000-0002-7976-3654), Tarella, C, Gavarotti, P, Caracciolo, D, Locatelli, Franco, Falda, M, Paolino, F, Lovisone, E, Sormano, E, Tassi, V, Urgesi, A, and Locatelli, F (ORCID:0000-0002-7976-3654)

Abstract

Twenty-one patients with high risk non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD) underwent autologous bone marrow transplantation (ABMT). Nine out of 21 patients received in addition to bone marrow (BM) cells also peripheral blood (PB) cells collected by leucapheresis performed in the recovery phase after high-doses of either cyclophosphamide or etoposide (7 patients), or after ara-C (2 patient). All patients receiving BM + PB cells had ABMT as salvage therapy following extensive relapse or progression of their disease. The addition of PB cells to BM cells allowed a significantly faster recovery after ABMT. Median time to reach WBC greater than 1,000/microL was 14 days versus 20.5 days for patients receiving BM only. Furthermore, a reduced requirement of supportive care and a shorter period of isolation was observed. These results confirm that PB cells combined with BM cells allow a prompt hematopoietic reconstitution after myeloablation. In addition, the data demonstrate the efficacy of PB cells collected after various cytotoxic drugs, even in patients previously exposed to cytoreductive regimens.

Published
1990

99. Lineage-specific requirement of c-`abl' function in normal hematopoiesis.

Author

Caracciolo, D. and Valtieri, M.

Subjects
*LEUKEMIA
Abstract

Describes research into structural abnormalities of the c-`abl' proto-oncogene found in hematopoietic cells of more than 90 percent of chronic myelogenous leukemia patients. Data show that c-`abl' is critical in normal myelopoiesis, and may explain the relatively selective expansion of leukocytes in these patients.

Published
1989
Full Text
View/download PDF

100. Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines

Author

Lange, B, Valtieri, M, Santoli, D, Caracciolo, D, Mavilio, F, Gemperlein, I, Griffin, C, Emanuel, B, Finan, J, and Nowell, P

Abstract

Eight permanent cell lines were established from cells of 50 consecutive patients with childhood acute leukemia. Three cell lines required growth factor-containing conditioned media. Analysis using blocking antisera and recombinant granulocytic macrophage (GM) colony- stimulating factor (CSF) identified GM-CSF as a growth factor required to establish the latter three cell lines and necessary for their continuous proliferation in chemically defined medium. Two of the GM- CSF-dependent cell lines were derived from patients with undifferentiated T- and a biphenotypic B-myelomonocytic leukemia, which suggests that GM-CSF might maintain proliferation of leukemias originating from immature progenitor cells. Cytogenetic analysis indicated that all established leukemic cell lines were aneuploid, with six lines containing chromosomal alterations related to those observed in the leukemic cells of the patient. Two patients did not have an abnormal clone identified in the marrow but did yield an aneuploid cell line. These studies indicate that GM-CSF-dependent leukemic cell lines can be established in a fraction of childhood leukemia. These cell lines lend themselves to studies aimed at the evaluation in vitro of the role of growth factors in controlling proliferation and differentiation of leukemic cells.

Published
1987
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results